Cancer Genetics Inc

Cancer Genetics — Q3 2017 Earnings Presentation

13 slides from Cancer Genetics's earnings presentation, Nov 9, 2017

  1. Slide 1: Forward-Looking Statements

    Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical develo

  2. Slide 2: Everything we do is focused on 1 key idea

    Everything we do is focused on 1 KEY idea .. deliver innovation & patient value by providing the most comprehensive capabilities For precision oncology development.

  3. Slide 3: Revenue & Growth Highlights

    Q3 Revenue Amounts in $ millions Revenue & Growth Highlights p.4 4-Year CAGR 52% $8.0M 4-Year CAGR 42% Full year Revenue Amounts in $ millions $6.6M $10.2M $18.0M $27M 2013 2014 2015 2016 $1.5M $4.2M $7.0M Q3 2014 Q3 2015 Q3 2016 Q3 2017

  4. Slide 4: Revenue & Operating Expenses

    Revenue & Operating Expenses Amounts in $ millions Driving Operational Efficiency and a Clear Path to Profitability Response Acquisition Operating expenses decreased by $2.3 million for the first 9 months of 2017 over the same period in 2016 based on streamlining operations. ~$200k of G&A expense in

  5. Slide 5: Revenues By Market & Customer Category

    Revenues By Market & Customer Category Biopharma Services Supports over 190 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 52 for immuno-oncology indications. $4.2M Clinical Services 11% increase in test count, driving a 7% increase in clinical revenue over Q3 2016 d

  6. Slide 6: Q3 2017 Financial Highlights

    Q3 2017 Financial Highlights Revenues of $8.0 million, 19% increase over $6.8 million in Q3 2016. Biopharma Services increased 10%; Clinical Services increased by 7%; and Discovery Services grew 280% year-over-year. Total Operating Expenses were $6.6 million, an increase of 4% from $6.3 million duri

  7. Slide 7: Q3 2017 Business Highlights

    Q3 2017 Business Highlights Frost & Sullivan acclaimed CGI’s advanced genomic & biomarker technologies that drive industry innovation in support of precision cancer treatment. Presented at 2017 Disruptive Growth Company Showcase, The MicroCap Conference, and hosted panel discussion on “The Convergen

  8. Slide 8: Income Statement Items

    Income Statement Items ($ in Thousands) Q3 2016 Q3 2017 9 mos 2016 9 mos 2017 Revenue $6,750 $8,028 $19,819 $21,598 Gross Profit $2,306 $3,440 $6,987 $8,767 Gross Margin (%) 34% 43% 35% 41% Research & Development (R&D) $1,594 $981 $4,806 $3,080 Sales & Marketing (S&M) $1,054 $1,301 $3,731 $3,437 Gen

  9. Slide 9: Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress

    Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress Biopharma bookings to billing ratio of 1.6 on $8.2M of Q3 2017 bookings Record quarterly biopharma bookings of $8.2M, up 134% year over year expected to drive future revenue increases 59% increase in biopharma projects from 12

  10. Slide 10: Industry Leading Capabilities in Expanding Field of Immuno-Oncology

    Confirm Expressed Somatic Mutations NGS: Whole Transcriptome Confirm by Sanger NGS: Exome / Oncology Panel Identify Somatic Mutations TMB & MSI HLA Type Epitope Prediction Immune Repertoire (PMBCs) Pathology Histology Neoantigen Validation KEY: DNA Analysis RNA Analysis Bioinformatic Analysis Indust

  11. Slide 11: 2017 Goals

    2017 Goals Multiple Myeloma NGS Panel [Mayo] Further Expansion in Asia-Pacific Integration of vivoPharm Launch IO capabilities for Drug Discovery & Repurposing Develop Genetic Counselor Network Expand Hereditary Service Offering Liquid Biopsy for Kidney Cancer Bioinformatics Center of Excellence in

  12. Slide 12: CGI Headquarters and Office Locations

    www.cgix.com www.cancergenetics.com CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHERFORD, NJ, USA #3-1-135/1A CNR Complex Mallapur Main Road, R.R. Dst. Hyderabad – 500 076, Telangana Phone: +91 040-2717-8178 HYDERABAD, INDIA Research Triangle Park 133 Southcente

  13. Slide 13: = if pnd

    = if pnd J INCORPORATED asoag WWW CANCERGENETICS.COM

Cancer Genetics — Q3 2017 Earnings Presentation on 6ix